Screener
Eikon Therapeutics, Inc. EIKN EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Eikon Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216791
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (87,337) | (71,383) |
| Interest income (expense), net | 4,380 | 3,160 |
| Other income (expense), net | (1) | (20) |
| Net loss and comprehensive loss | (82,958) | (68,243) |
| Impact of preferred stock extinguishments and modifications | — | (6,300) |
| Net loss attributable to common stockholders | $(82,958) | $(74,543) |
| Net loss per share attributable to common stockholders, basic and diluted | $(2.46) | $(26.91) |
| Weighted-average shares of common stock outstanding used in computing net loss per share attributable to common stockholders, basic and diluted | 33,700,550 | 2,770,352 |
Item 1. Condensed Financial Statements (Unaudited).
FAQ
- What is Eikon Therapeutics, Inc.'s EPS (basic)?
- Eikon Therapeutics, Inc. (EIKN) reported EPS (basic) of -$2.46 in Q1 2026.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Eikon Therapeutics, Inc.'s eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude